Breaking AI & Tech News Analyzed

British drugmaker GSK announced the acquisition of Boston‑based cancer specialist Nuvalent for $10.6bn (£7.9bn), securing two late‑stage non‑small cell lung‑cancer therapies and marking the biggest deal in the company’s history.Deal Structure and Late‑Stage AssetsThe transaction brings Nuvalent’s two next‑generation drugs—zidesamtinib and neladalkib—into GSK’s portfolio. Both are under FDA review, with decisions slated for September and November, and are slated for launch later this year if approved.Financial Scale and Revenue Projections$10.6bn purchase price (≈ £7.9bn)Each drug is projected to become a multi‑billion‑dollar blockbuster, potentially generating several billion dollars in annual sales.GSK expects the new assets to start contributing to profit from 2027.Strategic Impact on GSK’s Oncology AmbitionsUnder new CEO Luke Miels, GSK is accelerating its oncology push that began under former chief Emma Walmsley. The acquisition adds a ready‑made lung‑cancer platform and complements the recently bought food‑allergy biotech RAPT, aligning with GSK’s target of >£40bn in annual sales by 2031.Outlook: Market Position and Pipeline GrowthAssuming FDA approval, the two drugs could fill a tolerability gap for non‑smoking adults aged 40‑50, predominantly female, and strengthen GSK’s competitive stance against rivals. The deal also provides a launchpad for the late‑stage candidate Ris‑Rez, which could broaden GSK’s cancer portfolio beyond lung indications.

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.